Astellas Pharma is targeting an increase between 15 and 20 percent in its sales in Egypt this year, country manager told Amwal Al Ghad on Sunday.
The Japanese drugmaker aims to make sales in Egypt worth 120 million Egyptian pounds ($6.7 million) this year, compared with 100 million pounds in 2017, Astellas Egypt’s manager Ayman Eldeeb said.
“Our turnover in the Middle East region exceeds €100 million ($117.1 million) a year,” Eldeeb said, adding that the parent company opened a regional office in Dubai three years ago along with an office in Egypt.
“We already have six registered drugs in the Egyptian market; they are for the treatment of various kinds of cancers and urologic diseases,” Eldeeb said.
The company seeks to have two or three drugs to be registered in the Egyptian Ministry of Health soon, Eldeeb said.
